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Sleep disturbances are frequent in cancer patients during chemotherapy; the contributory role of restless 
legs syndrome (RLS) in this setting has never been assessed. 
Objectives 
This study investigated the role of RLS in causing sleep disturbances and altering the quality of life in cancer 
patients during chemotherapy. 
Methods 
Evaluation tools included the Pittsburgh Sleep Quality Index (PSQI), the RLS questionnaires, the Functional 
Assessment of Cancer Therapy-General, and the Hospital Anxiety and Depression Scale for quality of life 
and anxiety/depression assessment. The study population was 173 cancer patients. The questionnaires 
were administered during the third chemotherapy cycle. Patients positive for RLS were reassessed six 
months after the end of chemotherapy. 
Results 
In all, 58.8% of patients reported experiencing sleep disturbances (PSQI ≥ 5) and 20% screened positive for 
RLS. Neither sleep disturbances nor RLS was associated with anemia, neurotoxic cytotoxic drugs, or 
benzamide treatment. A direct relationship was found between the PSQI and RLS (P = 0.007); both PSQI 
and RLS scores were significantly associated with poor quality of life (P = 0.008 and 0.01, respectively) and 
anxiety (P = 0.0001 and 0.01, respectively). PSQI score also was associated with depression (P = 0.0001). 
RLS persisted in four of the 25 RLS-positive patients reassessed at six months after chemotherapy. RLS 
recovery was associated with a significant reduction in sleep disturbances and improvement in quality of 
life. 
Conclusion 
RLS can be a contributory factor in sleep disturbances in cancer patients undergoing chemotherapy. 
Screening for RLS could aid in tailoring a potentially more efficacious treatment of such disturbances. 
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Sleep disruption is common among cancer patients receiving chemotherapy.1, 2 and 3 Probably 
multifactorial, its underlying pathophysiology is not fully understood.4 Insomnia and other symptoms, such 
as pain, fatigue, and mood disturbance, often occur in clusters and can negatively impact patients' quality 
of life and possibly the outcome of their diseases.5 and 6 It recently has been suggested that fatigue, sleep 
disturbance, and depression stem from distinct biologic processes in which inflammatory signaling may be 
a contributory factor.7 
 
Restless legs syndrome (RLS), a neurologic condition that causes sleep and movement disorders, is defined 
as an irresistible desire to move the limbs. Usually associated with paresthesias/dysesthesias and motor 
restlessness, the symptoms start or worsen at rest and improve with activity. Worsening of symptoms in 
the evening and/or at night often results in disturbance of sleep and daytime tiredness.8 
 
RLS is generally considered to be idiopathic (primary) or symptomatic (secondary). The primary form (60%–
80% of all RLS) might be better defined as cryptogenic, indicating that in most cases the etiology and 
pathogenesis are uncertain, while leaving the possibility open of finding its exact origin and mechanisms. 
Secondary or RLS-associated conditions include end-stage renal disease, iron deficiency (with or without 
anemia), neuropathies and radiculopathies, rheumatoid arthritis, myelopathies, syringomyelia, Parkinson's 
disease, and pregnancy.9 
 
The prevalence of clinically significant RLS is estimated to be 2%–4% in the U.S. and Western Europe.10 
 
Most patients with RLS respond robustly to dopaminergic agents.11 Levodopa improves RLS but, because 
of its short half-life, the drug is associated with a high incidence of symptom rebound and augmentation. 
Augmentation, mainly characterized by the occurrence of RLS symptoms earlier in the day, is less 
frequently observed with dopamine agonists. Since ergot-derived compounds can cause pleural, 
pericardial, and retroperitoneal fibrosis, treatment with non-ergot dopamine agonists is preferred instead. 
Extensive data are available for pramipexole, ropinirole, and transdermal rotigotine in the treatment of 
RLS.12 
 
The prevalence of RLS among cancer patients rarely has been investigated.13 A recent study by our group 
demonstrated that RLS is frequent in cancer patients during chemotherapy, with a prevalence of 18%, 
which is at least double that expected in the general population. RLS is correlated with poor quality of life, 
anxiety, and depressive symptoms. Because the questionnaires were administered in a blinded format in 
our previous study, we were unable to search for clinical features associated with RLS.14 
 
The present study was undertaken to assess the contributory role of RLS in sleep disorders occurring in 
cancer patients during chemotherapy. The secondary aim was to explore the relationship of sleep disorders 
and RLS with demography and patient characteristics, laboratory data, treatments, and patient anxiety, 




From November 2008 to April 2009, all consecutive patients undergoing chemotherapy at the Day Hospital 
of the Medical Oncology Department, Azienda Ospedaliero-Universitaria San Luigi Gonzaga, Orbassano, 
Italy, who gave informed consent were included in the study if they met the following eligibility criteria: 
histologically confirmed diagnosis of cancer, chemotherapy treatment between the third and fourth cycle, 
adequate compliance with treatment, age >18 years, written informed consent, and Eastern Cooperative 
Oncology Group performance status <2.15 Exclusion criteria were major dopaminergic alterations (i.e., 
Parkinson's disease), other relevant neurologic disorders, treatment with neuroleptics, diagnosed 
psychiatric disorders and subsequent treatment with psychotropic agents including antidepressants (i.e., 
selective serotonin reuptake inhibitors), known history of RLS (before the start of chemotherapy), 
molecular target therapies administered alone, renal impairment and hepatic impairment defined as serum 
creatinine ≥1.5 × normal value, and total bilirubin, alanine aminotransferase, and aspartate 
aminotransferase defined as ≥1.5 × normal value. 
 
The following clinical data were retrieved from hospital records: primary site of malignancy, metastatic 
sites (if present), ongoing cancer treatment, concomitant drugs, concomitant medical conditions, and 
baseline hemoglobin level. 
 
Explorative information about the duration of RLS was obtained by reassessing RLS-positive patients at six 
months after the end of chemotherapy for RLS according to essential diagnostic criteria, the Functional 
Assessment of Cancer Therapy-General (FACT-G), the Hospital Anxiety and Depression Scale (HADS), and 
the Pittsburgh Sleep Quality Index (PSQI). No specific treatment for RLS was prescribed during this time. 
 
The study protocol was approved by the local ethics committee, and written informed consent was 
obtained from all patients before entry into the study. 
Questionnaires 
 
The PSQI16 assesses sleep quality; it measures subjective sleep quality in the preceding one-month period 
and comprises 19 self-rated questions and five questions rated by a bed partner or roommate. The 19 
items are grouped into seven component scores: sleep quality, sleep latency, sleep duration, sleep 
efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. The global PSQI score 
(range, 0–21) is calculated by summing the component scores, whereby a higher score indicates worse 
sleep condition. A global PSQI score of five has been suggested to distinguish poor (PSQI ≥ 5) from good 
sleepers (PSQI < 5), with diagnostic sensitivity of 89.6% and specificity of 86.5%. Internal consistency as 
measured by Cronbach's alpha was 0.78. 
 
The RLS essential diagnostic criteria9 were used for the diagnosis of RLS. All patients first completed this 
screening questionnaire. Those who identified the presence of RLS symptoms on the questionnaire 
subsequently underwent a structured interview conducted by two of the authors (L. F. S. and V. C.), both 
board-certified sleep medicine specialists, to confirm the diagnosis. Patients with clinical conditions that 
could mimic RLS symptoms (eg, neuropathic pain syndromes, leg akathisia, nocturnal leg cramps, and 
propriospinal myoclonus) were excluded.17 If the diagnosis of RLS was confirmed, the International 
Restless Legs Syndrome Study Group rating scale (IRLS)18 and 19 was administered to assess the severity of 
the condition. 
 
The FACT-G20 addresses health-related quality of life and was developed and validated for use in clinical 
trials. The FACT-G is a 29-item self-report questionnaire comprising five subscales: Physical Well-Being 
(PWB), Functional Well-Being (FWB), Social/Family Well-Being, Emotional Well-Being (EWB), and 
Relationship with Doctor (RWD). Each item is rated from 0 (not at all) to 4 (very much); the range of scores 
is 0–108, with higher scores indicating better quality of life. Patients were asked to rate how they felt that 
day and over the previous seven days. The internal consistency on all five subscales was good (Cronbach's 
alpha of at least 0.82). 
 
The HADS21 assesses levels of anxiety and depression. A simple but reliable tool to assess mood disorder in 
hospitalized populations and hospital outpatients, it consists of two subscales: one to determine anxiety 
status and one to determine depression status. Each subscale contains seven items that patients respond 
to on a 4-point (0–3) scale, where scores range from 0 to 21 for both anxiety and depression. For each 
subscale, a score of 0–7 indicates normal condition, 8–10 is suggestive of anxiety/depression, although not 
at the level of mood disorder, and 11 or higher indicates the probable presence of mood disorder. Patients 
were asked to indicate for each item how he/she felt in the past week. The internal consistency on the two 
subscales was good (Cronbach's alpha 0.81 and 0.74, respectively). 
 
The questionnaires were administered to all patients during their stay in the Day Hospital by two well-
trained nurses (B. R. and P. L. G.), who also were available to answer questions about completing the 
questionnaires. 
Statistical Analysis 
 The sample size of this study was calculated assuming a frequency of RLS in the general population as 10% 
(Ho) and an expected frequency of 18% in cancer patients (H1) on the basis of a previous publication by our 
group.14 For an alpha error of 0.05 and a power of 90%, 172 patients had to be enrolled to demonstrate 
such a difference. 
 
Normal distribution of continuous variables was assessed using the Kolmogorov-Smirnov test. The t-test or 
Mann-Whitney U test, when indicated, was applied for comparisons of continuous variables. Chi-square or 
Chi-square for trend, when indicated, was employed for comparisons of categorical variables. The 
nonparametric Wilcoxon rank-sum test and Kruskal-Wallis test were used, when applicable, to compare 
paired continuous variables. All statistical tests were two-sided and, taking into account the multiple 
comparisons performed, a P ≤ 0.01 was considered statistically significant. All statistical analyses were 




A total of 173 patients (94 [54.3%] males and 79 [45.7%] females) were included in the study (Table 1). 
Chemotherapy was administered in an adjuvant setting to 60 (34.7%) patients and to 113 (65.4%) patients 
for advanced or metastatic disease. 
 
    Table 1. 
 
    Patient Characteristics and Treatments Administered 
    Variable n % 
    Sex (n=173) 
    Male 94 54.3 
    Female 79 47.7 
    Age (years), mean±SD (range) 58.8±12.3 (20–80) 
    Site of primary tumor (n=173) 
    Colon-rectum 56 32.4 
    Breast 30 17.3 
    Prostate 13 7.5 
    Ovary 11 6.4 
    Bladder 10 5.8 
    Gastroenteropancreatic neuroendocrine 10 5.8 
    Pancreas 6 3.5 
    Testis 6 3.5 
    Stomach 6 3.5 
    Lung 5 2.9 
    Adrenal cortical 5 2.9 
    Uterus 4 2.3 
    Kidney 4 2.3 
    Head and neck 3 1.7 
    Thymus 2 1.2 
    Esophagus 1 0.6 
    Thyroid 1 0.6 
    Sites of metastases (n=112) 
    Liver 52 46.4 
    Lung 31 27.7 
    Nodes 28 25.0 
    Bone 27 24.1 
    Peritoneum 16 14.3 
    Local relapse 9 8.2 
    Other 12 10.7 
    Anemic patients 34 19.7 
    Patients treated with opioids 20 11.6 
    Patients treated with benzamides (metoclopramide, levosulpiride) 100 57.8 
    Treatment administered 
    Non-neurotoxic drugs 61 35.2 
    Potentially neurotoxic drugs 112 64.8 
    Cisplatin/carbopatin/oxaliplatin-containing regimens 69 39.9 
    Taxanes/vinca alkaloids/camptothecine derivative-containing regimens 43 24.9 
    Table options 
 
The most frequent primary malignancies were colorectal (32.4%), breast (17.3%), and prostate (7.5%) 
cancer. The most frequent metastatic sites were liver (46.4%), lung 31 (27.7%), lymph nodes 28 (25%), and 
bone 27 (24.1%). 
 
Potentially neurotoxic chemotherapeutic agents were administered to 90 (52.3%) patients; the remaining 
83 patients received non-neurotoxic therapies consisting of anthracyclines, cyclophosphamide and other 
nitrogen mustards, fluoropyrimidines (both oral and intravenous), antimetabolites, and 
epipodophyllotoxins (Table 1). 
Frequency of Sleep Disturbances and RLS 
 
In all, 153 (88.4%) patients completed the PSQI questionnaire. The majority (mean ± SD, 6.14 ± 3.95) 
reported experiencing sleep disruption during chemotherapy: 90 (58.8%) patients had a PSQI score ≥5 
(overall poor sleep quality), 28 (18.3%) rated their sleep quality as fairly/very bad, 100 (65.4%) reported 
increased sleep latency, and 63 (41.2%) reported sleeping less than seven hours per night. In addition, 49 
(42.0%) patients reported using a sleep medication at least once during the prior month and 95 (62.1%) had 
experienced daytime dysfunction as the result of poor sleep. 
 
All patients completed the RLS questionnaires; 38 met all the essential screening criteria for RLS, but two 
were excluded from the analysis because of a neuropathic pain syndrome. Thus, 36 patients (20.8%) met all 
the essential diagnostic criteria for RLS and the diagnosis was confirmed by means of a structured interview 
and evaluation conducted by a sleep medicine specialist (L. F. S.). On the basis of the IRLS severity score,19 
eight (22.2%) patients showed mild RLS, 14 (38.9%) moderate RLS, 12 (33.3%) severe RLS, and two (5.6%) 
very severe RLS. 
Relationship of Sleep Disturbance and RLS With Patient Characteristics and Cancer Treatment 
 
The frequency of episodes of sleep disturbances and RLS was assessed by stratifying the patients according 
to their characteristics and type of treatment. As depicted in Table 2, sleep disturbances (PSQI ≥ 5) were 
more frequent among females than males but failed to correlate with age, anemia, and treatment with 
opioids, benzamides, and neurotoxic chemotherapeutic regimens. Also, the mean corpuscular volume 
values were similar in the RLS patients (median 86.4 fL [95% CI 85.5–91.4]) as opposed to their 
counterparts (median 88.3 fL [95% CI 86.6–93.8]) (P = 0.288). Furthermore, there was no difference in the 
distribution of RLS frequency between metastatic and non-metastatic status and the most frequent primary 
sites of malignancy. 
     Table 2. 
 
    Distribution of Sleep Disturbances and RLS According to Demographic Characteristics, Laboratory 
Parameter, Supportive Drug Intake, and Chemotherapy Neurotoxic Regimens 
    Variable RLS (n = 36), n (%) P Sleep Disturbances, n (%) P 
    Gender 
    M 17/94 (18.0) 0.34 45/82 (54.9) 0.048 
    F 19/79 (24.0) 50/71 (70.4) 
    Age 20–55 years (1° tertile) 13/59 (22.0) 0.23a 37/55 (67.3) 0.60a 
    Age 56–65 years (2° tertile) 16/59 (27.1) 31/54 (57.4) 
    Age 66–80 years (3° tertile) 7/55 (12.7) 27/43 (62.7) 
    Anemia 7/39 (17.9) 0.92 20/31 (64.5) 0.85 
    No anemia 28/134 (20.9) 75/114 (65.7) 
    Opioid treatment 6/20 (30) 0.28 9/16 (56.2) 0.61 
    No opioid treatment 27/153 (19.6) 86/137 (62.8) 
    Benzamide treatment 21/100 (21) 0.94 48/83 (57.8) 0.24 
    No benzamide treatment 13/73 (20.5) 47/70 (67.1) 
    Non-neurotoxic regimens 15/61 (24.6) 0.31a 35/55 (63.6) 0.55a 
    Taxanes/vinca alkaloid/camptothecin derivative-containing regimens 8/43 (20.9) 25/38 (65.7) 
    Cisplatin/carbopatin/oxaliplatin-containing regimens 12/69 (17.4) 35/60 (58.3) 
    Non-metastatic 14/61 (23) 0.67 33/61 (54.1) 0.93 
    Metastatic 22/112 (19.6) 62/112 (55.4) 
    Breast primary site 7/30 (23.3) 0.81 18/30 (60.0) 0.61 
    Colon/rectum primary site 9/56 (16.1) 29/56 (51.7) 
    Prostate primary site 3/13 (23.1) 6/13 (46.2) 
 
    RLS = restless legs syndrome; M = male; F = female. 
     a 
 
        Chi-square for trend. 
 
    Table options 
 
Relationship Between RLS and Sleep Disorders 
 
Among the 90 patients classified as “poor sleepers,” 26 (28.8%) were affected by RLS, whereas 10 of 63 
“good sleepers” (15.8%) had RLS. The relationship between RLS and sleep disorders is depicted in Table 3. 
There was a significant progressive increase in the total PSQI score as RLS severity increased (P = 0.007). 
Considered as categorical variables, the scores for the single items on the PSQI showed a trend for a step-
wise deterioration in the quality of sleep (P = 0.011) and an increase in the use of sleep-inducing drugs, 
such as benzodiazepines (P = 0.023), together with an increase in RLS severity. Noteworthy was that both 
severe anxiety and severe depression correlated in a step-wise manner with RLS severity (P = 0.0008 and P 
= 0.0007, respectively) (Table 3). 
 
    Table 3. 
 
    Relationship of RLS With Sleep Disorders 
    Psychometric Evaluation No RLS n (%) Mild-to-Moderate RLSn (%) Severe-to-Very Severe RLSn 
(%) P 
    PSQI 
    Quality of sleep (fairly/very bad) 18/121 (14.9) 4/18 (22.2) 6/14 (42.8) 0.011 
    Sleep latency 76/121 (62.8) 12/18 (67.1) 12/14 (85.7) 0.11 
    Sleep duration <7 hours 47/121 (38.8) 8/18 (44.4) 8/14 (57.1) 0.19 
    Sleep efficacy (<85%) 54/121 (44.6) 6/18 (33.3) 11/14 (78.5) 0.09 
    Sleep disturbances during last month (at least one per week) 102/121 (84.3) 18/18 (100) 13/14 (92.8)
 0.20 
    Intake of sleep-inducing drugs 34/121 (28.1) 7/18 (38.9) 8/14 (57.1) 0.023 
    Daytime dysfunction 73/121 (60.3) 10/18 (55.5) 12/14 (85.7) 0.15 
    Total PSQI score, mean±SD 5.64±3.52 6.78±4.62 10±4.8 0.007 
    HADS 
    No anxiety 81/121 (66.9) 11/18 (61.1) 0/14 (0) 0.01 
    Moderate anxiety 21/121 (17.4) 4/18 (22.2) 3/14 (21.4) 0.66 
    Severe anxiety 19/121 (15.7) 3/18 (16.6) 11/14 (78.6) 0.0008 
    No depression 90/121 (74.4) 13/18 (72.2) 4/14 (28.5) 0.15 
    Moderate depression 22/121 (18.8) 3/18 (16.6) 3/14 (21.4) 0.87 
    Severe depression 9/121 (7.4) 2/18 (11.1) 7/14 (50) 0.0007 
    Total HADS score, mean±SD 12.01±6.51 13.13±8.92 22.29±5.92 0.008 
    FACT-G, mean±SD 
    PWB 22.21±5.05 21.11±4.35 12.35±9.11 0.0001 
    Social Well-Being 18.16±4.34 17.27±5.59 18.71±3.11 0.35 
    RWD 6.27±1.76 6.27±1.49 6.21±1.93 0.94 
    EWB 6.42±4.47 7.27±5.14 6.22±3.01 0.03 
    FWB 15.76±5.45 15.82±4.95 11.76±4.41 0.04 
    Total FACT-G score 69.13±9.06 68.35±9.86 60.58±7.94 0.05 
 
    RLS = restless legs syndrome; PSQI = Pittsburgh Sleep Quality Index; HADS = Hospital Anxiety and 
Depression Scale; FACT-G = Functional Assessment of Cancer Therapy-General scale; PWB = Physical Well-
Being; RWD = Relationship with Doctor; EWB = Emotional Well-Being; FWB = Functional Well-Being. 
 
    Table options 
 
Evaluation of quality of life showed a trend of a progressive decrease in the total FACT-G score with 
increased RLS severity (P = 0.05): PWB subscale scores significantly decreased as RLS severity increased (P = 
0.0001) (Table 3). 
Relationships of Sleep Disturbances and RLS With Quality of Life, Anxiety, and Depression 
 
Sleep disturbances were significantly associated with lower quality of life scores (P = 0.01): sleep 
disturbances were associated with lower FWB (P = 0.0001) and higher EWB scores (P = 0.002). No 
significant correlation emerged for Social/Family Well-Being, RWD, and FWB. Also, anxiety (P = 0.0001), 
depression (P = 0.0001), and total HADS scores (P = 0.0001) were significantly associated with sleep 
disturbances (Table 4). 
 
    Table 4. 
 
    Relationship Between Sleep Disturbances and RLS With Quality of Life, Anxiety, and Depression 
    Psychometric Evaluation No (Mean ± SD) Yes (Mean ± SD) P 
    FACT-G 
    Restless leg syndrome    
    PWB 22.21±5.05 6.61±5.65 0.0001 
    Social Well-Being 18.16±4.34 18.28±4.73 0.796 
    RWD 6.27±1.76 6.17±1.71 0.896 
    EWB 9.39±5.80 6.41±4.47 0.002 
    FWB 15.76±5.45 13.74±5.21 0.05 
    Total Fact-G score 69.13±9.06 65.38±10.16 0.01 
    Sleep disturbances    
    PWB 22.88±4.49 20.20±6.81 0.027 
    Social Well-Being 18.56±3.27 17.93±5.01 0.99 
    RWD 6.57±1.59 6.05±1.82 0.084 
    EWB 4.67±3.32 8.39±5.13 0.0001 
    FWB 18.48±4.83 13.47±4.91 0.0001 
    Total Fact-G score 71.24±8.64 66.51±9.39 0.008 
    HADS 
    Restless legs syndrome    
    Anxiety 6.57±3.81 9.94±5.41 0.01 
    Depression 5.43±3.58 7.22±4.66 0.03 
    Total HADS score 12.01±6.51 17.16±9.42 0.005 
    Sleep disturbances    
    Anxiety 5.44±3.26 8.56±4.49 0.0001 
    Depression 3.98±2.79 7.14±4.05 0.0001 
    Total HADS score 9.42±4.79 15.70±7.75 0.0001 
 
    RLS = restless legs syndrome; PWB = Physical Well-Being; RWD = Relationship with Doctor; EWB = 
Emotional Well-Being; FWB = Functional Well-Being; FACT-G = Functional Assessment of Cancer Therapy-
General scale; HADS = Hospital Anxiety and Depression Scale. 
 
    Table options 
 
RLS was significantly associated with the poorest quality of life (P = 0.01): lower levels of PWB (P = 0.0001) 
and EWB (P = 0.002) were observed in patients with RLS. RLS-positive patients were noted to have higher 
levels of anxiety (P = 0.01) and higher total HADS scores (P = 0.005) (Table 4). 
Reassessment of Patients Screening Positive for RLS 
 
Of the 36 patients initially screening positive for RLS, 25 could be reassessed at six months after the end of 
chemotherapy. The remaining 11 were not evaluable because of worsening of clinical condition (n = 4), 
death (n = 6), and refusal (n = 1). 
 
On reassessment, four patients still met all the essential diagnostic criteria for RLS and 21 did not. 
Specifically, a comparison between quality of life, anxiety and depression levels, and quality of sleep at the 
first assessment during chemotherapy (T0) vs. that at reassessment (T1) was performed. Among the 21 
patients who recovered from RLS, a significant improvement in quality of life was noted, particularly for 
PWB (P = 0.0001), RWD (P = 0.01), EWB (P = 0.0001), and total FACT-G score (P = 0.001), as well as quality 
of sleep (P = 0.01), although the levels of anxiety and depression did not differ significantly between T0 and 
T1 (Table 5). Conversely, no improvement in quality of life, sleep quality, or levels of anxiety and depression 
was found for the four patients who did not recover from RLS: the values of the total scores and the single 
items on the FACT-G, HADS, and PSQI were substantially unchanged between T0 and T1 (data not shown). 
 
    Table 5. 
 
    Changes in Quality of Life, Anxiety, Depression, and PSQI Score in 25 Patients With RLS Resolution After 
the End of Chemotherapy 
    Psychometric Evaluation T0 (Mean ± SD) T1 (Mean ± SD) P 
    PWB 6.05±5.63 19.22±7.01 0.0001 
    Social Well-Being 15.31±5.23 15.56±3.95 0.796 
    RWD 5.86±1.64 6.64±1.48 0.01 
    EWB 6.69±3.80 15.53±4.94 0.0001 
    FWB 15.33±5.67 14.17±5.39 0.265 
    Total Fact-G score 49.14±9.68 72.97±13.38 0.001 
    Anxiety 9.65±5.29 9.46±4.77 0.806 
    Depression 7.11±4.43 7.01±4.05 0.866 
    Total HADS score 16.76±8.76 16.46±7.73 0.795 
    Total PSQI score 7.64±4.44 6.08±3.56 0.01 
 
    PSQI = Pittsburgh Sleep Quality Index; RLS = restless legs syndrome; PWB = Physical Well-Being; RWD = 
Relationship with Doctor; EWB = Emotional Well-Being; FWB = Functional Well-Being; FACT-G = Functional 
Assessment of Cancer Therapy-General scale; HADS = Hospital Anxiety and Depression Scale. 
 




Sleep disturbances are frequent in cancer patients receiving chemotherapy.22 and 23 The pathophysiology 
underlying these disturbances is notoriously complex and multifactorial.24 Such disturbances are often 
secondary to disease-associated pain, fatigue, patient anxiety, and/or depression linked to uncertainties 
about treatment outcome, drug interactions, or psychosocial factors. Moreover, primary sleep disorders 
including obstructive sleep apnea, periodic limb movements (PLMs), and RLS, although common in the 
general population,25 and 26 have received little attention from the oncology community. 
 
The present study confirms the high prevalence of sleep disorders in cancer patients during chemotherapy. 
We observed that RLS also is frequent. The proportion of 20% of RLS-positive patients is similar to that 
observed in our precedent series and is consistently higher than the expected frequency in the general 
population. Noteworthy is that RLS was severe in 8% of the patients in this study. 
 
As expected, both RLS and sleep disorders were associated with worse quality of life and greater anxiety 
and depression. Future studies will need to address whether these conditions can be improved with early 
treatment of RLS. 
 
The mechanisms underlying the occurrence of RLS in cancer patients are unknown and both cancer-related 
and treatment-related causes can be considered. To limit potential biases, patients with renal impairment 
or currently treated with selective serotonin reuptake inhibitors were excluded from this study. In our 
series, none of the predictive factors of RLS in the general population (e.g., sex, anemia) were significantly 
associated with the development of this disturbance. The presence of iron deficiency was not directly 
assessed in this study, but mean corpuscular volume values, as a marker of iron status, did not differ 
between the RLS-positive and RLS-negative patients. 
 
Among the 25 RLS-positive patients who could be reassessed six months after the end of chemotherapy, 
the disorder persisted in only four of them. This observation suggests a causative role of cytotoxic 
treatment in RLS onset. Many chemotherapeutic drugs are, in fact, neurotoxic. Added to these are 
frequently used antiemetic drugs, such as benzamides, which interfere with the dopamine system and so 
may lead to RLS. In this study, however, no correlation was found between RLS and either neurotoxic 
chemotherapy or benzamides. Other mechanisms, therefore, need to be taken into account. Moreover, 
because RLS not infrequently shows an intermittent pattern, a longer follow-up is needed to assess this 
phenomenon.27 Noteworthy is that no improvement in quality of life, anxiety and depression, or sleep 
disturbances was observed in the four patients with persistent RLS, suggesting a link between RLS and 
psychophysical impairment. 
 
As reported in a recent Cochrane review,28 levodopa in the short-term treatment of RLS is efficacious by 
reducing symptom severity and PLMs during sleep. Dopamine agonists were associated with greater 
improvement on IRLS scores compared with placebo.29 Also, the occurrence of PLMs was found to be 
significantly reduced by dopamine agonists compared with placebo, and sleep efficiency also was slightly 
improved. Although the patients rated their quality of sleep and quality of life as markedly improved, they 
were more likely to discontinue dopamine agonist treatment compared with placebo. 
 
Among the 28 RLS-positive patients who were assessed for sleep disturbances, 15 (53.6%) reported using a 
benzodiazepine as a sleep inducer. Data supporting the use of benzodiazepines for RLS are scarce. Although 
several studies showed that benzodiazepines may improve sleep quality in RLS patients, their therapeutic 
effects on RLS symptoms have been reported to be either modest or nonsignificant.30 In a recently 
published prospective study, switching from clonazepam to pramipexole in patients with RLS was 
associated with a significant reduction in RLS-related symptoms.31 
 
The strengths of this study are the relatively large number of patients consecutively enrolled at a single 
institution and the number of psychometric tools administered. Although patients with known RLS before 
beginning chemotherapy were excluded, the absence of RLS assessment at baseline is a limitation. Another 
limitation is that the diagnosis of RLS was not confirmed by polysomnographic evaluation. It should be 
noted, however, that the number of PLMs and the number of arousals (an expression of sleep 
fragmentation) vary from night to night in RLS patients.32 Polysomnographic evaluation for several nights 
would necessarily have involved additional visits to the study center, which might not have been willingly 
accepted by a population of cancer patients during chemotherapy. 
 
In conclusion, this study confirms that sleep disturbances are highly prevalent in cancer patients 
undergoing chemotherapy and are associated with a significant burden on the individual in terms of 
functional impairment, reduced quality of life, and increased anxiety and depression. RLS is a frequent 
cause of sleep disturbances during chemotherapy. Further study is needed to determine whether this 
adverse event is transient or not. The diagnosis of RLS is clinical9 but it is usually misdiagnosed unless 
validated questionnaires are administered. We believe that screening for RLS in patients during 
chemotherapy is important because it can aid in tailoring a possibly more efficacious treatment of sleep 
disturbances. The best therapeutic approach to RLS during chemotherapy warrants a prospective 
randomized clinical trial. 
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